Abstract:
Methods, devices, systems of resuscitating a patient including accessing an arterial vessel positioning a catheter into the arterial vessel advancing the catheter through the arterial vessel to position it below a vessel supplying blood to a heart and a brain expanding an expandable portion of the catheter to prevent blood from flowing past the expanded portion and infusing a substance retrograde into the artery within the arterial section between the bean and the expanded portion of the catheter.

Description:
RELATED APPLICATION DATA 
       [0001]    This application is a non-provisional of U.S. Provisional Application No. 62/265,336 filed Dec. 9, 2015, the entirety of which is incorporated by reference. This application also incorporates by reference U.S. Provisional No. 61/727,302 filed on Nov. 16, 2012, entitled RESUSCITATION SYSTEM AND METHOD OF USE; and U.S. patent application Ser. No. 14/083,192 filed on Nov. 18, 2013, entitled SYSTEMS, DEVICES AND METHODS FOR RESUSCITATION. 
     
    
     FIELD OF THE INVENTION 
       [0002]    The present invention relates to an injection system for administering medical substances into tissue. Variations of the device and method described herein allow for an automated injector for administration of medications under the skin or into the muscle of patients. Further variations include injection systems designed to reside on an individual where injection of the substance can occur when needed and on-demand. 
       BACKGROUND 
       [0003]    The survival rate is relatively low for a person, whether in a medical setting or elsewhere, is relatively low. One of the reasons for the high mortality rate is that cardiopulmonary resuscitation (CPR), one of the primary resuscitation methods, induces little forward blood flow. Although certain drugs, such as epinephrine, can improve vital organ blood flow during CPR, these drugs are administered almost exclusively into a vein; as such, the drug must circulate to and through the heart and lungs before arriving at the peripheral arteries where their primary beneficial pharmacological effects occur. During this low blood state of CPR, the heart and brain receive very limited blood flow blood that may fail to sustain cellular survival. 
         [0004]    Invasive techniques such as open-chest cardiac massage (OCCM), direct mechanical ventricular assistance (DMVA), and cardiopulmonary bypass (CPB) can provide better vital organ blood flow. See generally R. Bartlett et al., Ann. Emerg. Med. 13(Part 2), 773-777 (1984); M. Anstadt et al., Resuscitation 21,7-23 (1991); P. Safar et al., Am. J. Emerg. Med. 8, 55-67 (1990). However, adaptation of these techniques for widespread use, particularly in a setting outside a hospital, is unrealistic. In most cases, the response time that would enable significant neurologic recovery would likely expire before these techniques could be employed in a typical emergency. 
         [0005]    Selective aortic arch perfusion (SAAP) is a technique designed to provide relatively isolated perfusion of the heart and brain in patients suffering cardiac arrest. SAAP is typically performed by inserting a large lumen balloon occlusion catheter, percutaneously or by surgical cutdown, into a femoral artery and then advancing the catheter tip to the descending aortic arch, preferably just distal to the left subclavian artery. With the SAAP catheter balloon inflated to prevent or restrict distal aortic flow, the coronary and cerebral circulations can be relatively selectively perfused with a solution infused via the lumen of the SAAP catheter. The infused solution is typically an oxygenated blood substitute, such as a perfluoro carbon emulsion or polymerized hemoglobin solution that contains various agents capable of reversing ischemic metabolic processes, restoring peripheral vascular resistance, correcting hemostatic derangements, and limiting reperfusion-induced cellular damage. For example, vasoconstrictors such as epinephrine are beneficial. Perfusion with such a solution can enhance return of spontaneous cardiac function and facilitate neuronal functional recovery. Catheters intended to occlude the descending aorta are disclosed by Manning, U.S. Pat. Nos. 5,678,570, 5,216,032, and Paradis, U.S. Pat. No. 5,334,142 each of which is incorporated by reference herein. 
         [0006]    Although research indicates that SAAP shows promise, the technique has certain shortcomings. SAAP is a volume loading procedure and, as such, is volume limiting. When excess volumes of protective solution are infused, as may happen if an initial SAAP infusion is insufficient to resuscitate the patient and is followed by subsequent infusions, pulmonary congestion and edema can result, each of which can have a significant adverse effect on pulmonary oxygenation. The conventional devices do not optimally address avoidance of volume overload during SAAP. 
       SUMMARY OF THE INVENTION 
       [0007]    The devices and methods described herein improve shortcomings in SAAP treatment. The disclosure includes methods and devices for resuscitating a patient. For example, the method can include accessing an arterial vessel; positioning a catheter into the arterial vessel; advancing the catheter through the arterial vessel to position it below a vessel supplying blood to a heart and a brain; expanding an expandable portion of the catheter to prevent blood from flowing past the expanded portion; infusing a substance retrograde into the artery within the arterial section between the heart and the expanded portion of the catheter. 
         [0008]    In a variation of the method, accessing the arterial vessel involves identifying the location of the arterial vessel by a technique selected from the group consisting of a) feeling for a pulse and inserting the access device at the pulse; b) using ultrasound; c) using an electric field; d) using a magnetic field disturbance; and e) using tissue density differences. 
         [0009]    In another variation, where positioning the catheter further comprises placing a needle through the skin and overlying tissue into the artery; placing a wire through the needle; and placing the catheter over the needle or over the wire after removing the needle. 
         [0010]    The method can also further comprise determining the position below the vessel supplying blood to the heart and the brain is determined by a technique selected from the group consisting of: a) determining the distance from the access site to a desired position external to the patient and advancing the catheter to said predetermined distance; b) using xray to place the catheter into appropriate position and to verify that the catheter is in appropriate position; c) detecting a signal from the catheter (light, sound, ultrasonic, heat, cold, electromagnetic to determine placement position. 
         [0011]    In another variation, expanding the expanded portion comprises a device selected from the group consisting of a) a balloon catheter; b) a catheter with an umbrella structure; c) a catheter having a mechanically expanding spheroid. 
         [0012]    The substances used in the methods and device can include a) blood; b) oxygen carrier such as a perflourocarbon; c) calcium; d) EDTA; e) saline; f) cooling or warming fluid. 
         [0013]    The retrograde infusion can be continuous or pulsatile. 
         [0014]    A variation of the method includes the retrograde infusion supplied at a rate and or pressure sufficient to close the aortic valve. 
         [0015]    The devices described herein also include a catheter capable of performing the methods described here. Such a catheter can have the following characteristics: a) a proximal end; a distal end; a lumen connecting the proximal end to the distal end; an occluding part at the distal end that can be activated from outside the patient to occlude the flow of fluid on the outside of the lumen past itself. 
         [0016]    The occluding part of claim can be one of the following: a balloon; an expandable covered cage; side port suction that draws vessel around the part. 
         [0017]    In a variation, the device can include a pump to inject fluid from the proximal end of the device described herein such that it flows to the distal end of the catheter and into the blood vessel in a retrograde direction so as to increase the pressure in the vessel and close a valve such as the aortic valve when the vessel is the aorta, thereby directing flow of the injected fluid into side branches of the vessel such is into the coronary arteries and carotid arteries. 
         [0018]    The disclosure also includes an infusion substance that consists of at least one of the following: saline; oxygen carrier such as blood or a fluorocarbon based oxygen carrier; epinephrine; atropine; calcium chelator such as EDTA, calcium salts such as calcium gluconate and calcium carbonate. 
         [0019]    Another device includes a device for locating and cannulating a blood vessel consisting of a channel through which a needle or catheter can be placed from the outside of a patient to the inside of a blood vessel, a feedback system that provides information to the user that further makes it possible for the vessel to be located and for the catheter to be placed therein. Such a feedback method can include a least one of the following: a light pattern; a color change; a screen showing an image; a sound; a vibration; a temperature change; 
         [0020]    The light pattern described herein can include light changing from red to green when the device of claim  5  is correctly placed over a blood vessel to allow cannulation. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0021]      FIG. 1  is a schematic illustration of a balloon catheter inserted through the femoral artery into the aorta in a human subject proximal to the diaphragm but distal to the left subclavian artery, with the balloon inflated to block the descending aorta. 
           [0022]      FIG. 2  is an enlarged partial view of the heart and balloon catheter of  FIG. 1  showing the balloon catheter positioned to block the descending aorta and perfuse the aortic arch. 
           [0023]      FIG. 3  is a schematic illustration of a triple lumen balloon catheter having a blood withdrawal line configured to withdraw blood from the distal aorta. 
           [0024]      FIG. 4  is a schematic representation of a blood withdrawal catheter having an anticoagulant infusion port. 
           [0025]      FIG. 5  is a schematic illustration of an exemplary SAAP system and its catheter extending into the femoral artery of a subject. 
           [0026]      FIGS. 6A and 6B  illustrate variations of devices that rely on a perfusion substance to inflate an occlusive expandable member. 
           [0027]    FIGS. 7 A and  7 B illustrate a partial cross sectional view of the expandable member showing a valve located within the expandable member.  FIG. 7B  illustrates the valve in a closed position. 
           [0028]      FIGS. 8A and 8B  illustrate the valve in a closed position and in a released position using a release mechanism. 
       
    
    
     DETAILED DESCRIPTION 
       [0029]    The present invention will now be described hereinafter in detail with reference to the accompanying drawings. The present invention is not, however, limited to the embodiments described herein; rather, these embodiments are intended to enable those skilled in this art to understand fully the invention. 
         [0030]    As described above, the disclosure is directed to methods and associated apparatus for treating a subject in cardiac arrest. As used herein, the term “cardiac arrest” refers to all types of cardiac arrest, including ventricular fibrillation, asystole, and pulseless electrical activity. The subject of such cardiac arrest can be mammalian and more preferably human, but can be any animal that can be advantageously treated by oxygenating its brain and coronary vasculature during cardiac arrest. 
         [0031]    Blocking of the descending aorta, and infusion into the aortic arch, can be carried out with a balloon catheter unit such as that illustrated at  5  in  FIG. 1 . The balloon catheter unit  5  comprises an elongate catheter tube  6  having a primary lumen  7  through which protective solution may pass, and further comprises a balloon  8  at one end of the elongate tube  6  configured to be inflated to block the descending aorta of a human subject. A secondary tube  9  (or alternatively a secondary lumen formed in the wall of the tube  6  and extending longitudinally therewith) provides a mechanism for inflating the balloon  8  once the balloon  8  is positioned in the desired location within the descending aorta of the subject. A connector such as a Leur Lock™ fitting is provided at the end of the elongate tube  6  opposite the balloon  8  to connect the catheter tube  6  to a supply for the protective solution. 
         [0032]    For a human adult, the size of the primary lumen  7  may be from 6 French to 14 French, the length of the catheter tube  6  may be from 50 to 150 centimeters, the inflated dimensions of the balloon  8  may be from 1.5 to 4 centimeters in diameter, the length of the balloon  8  may be from 2 to 10 centimeters, and the distance from the tip of the catheter tube  6  to the balloon  8  distance may be from 1 to 4 centimeters. For a human child, the lumen size may be from 5 French to 10 French, the catheter tube length may be from 20 to 80 cm, the balloon inflated dimensions may be from 0.75 to 2 cm in diameter, the balloon length may be 1.5 to 6 cm, and the catheter-tip to balloon distance may be from 0.5 to 2 cm. When inflated, the balloon  5  should be capable of withstanding a pressure of at least 300 to 500 mmHg to prevent leakage of protective solution down the descending aorta and rupture of the balloon during chest compression. 
         [0033]    The catheter tube  6  may be made from a firm but somewhat flexible plastic material, and the balloon  8  from a latex or polyurethane material. The catheter tube  6  may be made from antithrombotic materials, such as having heparin bonding as a characteristic of construction, to inhibit formation of blood clots in the aorta. Reference may be made to U.S. Pat. Nos. 5,049,132; 5,049,131; 5,045,061; 5,042,976; 5,041,125; and 5,216,032 for further guidance in the construction of the balloon catheter. It is specifically intended that the disclosures of all patent references cited herein be incorporated herein by reference. 
         [0034]    To block the descending aorta of the subject ( FIGS. 1 and 2 ), the balloon catheter unit:  5  is inserted into a femoral artery  10  of the subject and advanced within the descending aorta  11  past the renal arteries  12 ,  13 , the superior mesenteric artery  14 , the celiac trunk  15 , the diaphragm  16 , and past various ones of the intercostal arteries  17 . The balloon  8  can be positioned distal to the carotid arteries  22 ,  24  and the left subclavian artery  21 , but can be located at least proximal to the renal arteries  12 ,  13 . The balloon  8  is inflated via the secondary tube  9  to block the descending aorta  11 , with the leading end of the elongate tube  6  positioned to perfuse the aortic arch  20 . In this position, protective solution pumped or forced through the balloon catheter unit  5  and exiting the balloon  8  will perfuse the left subclavian artery  21 , the left common carotid artery  22 , the brachiocephalic trunk  23  (and in turn the right carotid artery  24  and the right subclavian artery  25 ) and the coronary arteries  26 ,  27 . Although some variations block the descending aorta with a balloon catheter as illustrated, those skilled in this art will appreciate that other means for blocking the descending aorta to prevent flow therein can also be used with the present invention. 
         [0035]    Withdrawing the subjects blood can be carried out in any manner known to those skilled in this art to be suitable therefor. One technique of withdrawing autologous blood from the subject is to insert a catheter into the femoral vein (or some other large vein, such as the jugular vein or subclavian vein). This technique would allow blood to be continuously withdrawn and infused. Another technique would be to withdraw the blood from the proximal aorta with the balloon of the balloon catheter deflated. An alternative technique would involve withdrawing blood from the distal aorta with the balloon inflated, which is beneficial due to the capability of continuous infusion and withdrawal. A catheter embodiment for such withdrawal is illustrated schematically in  FIG. 3 . A balloon catheter unit  30  comprises two large lumens: an infusion lumen  31  that terminates beyond the balloon  32 ; and a blood withdrawal lumen  33  that terminates prior to the balloon  32 . A balloon inflation line  34  terminates within the balloon  32 . This embodiment enables blood to be withdrawn into the blood withdrawal lumen  33  either when the balloon  32  is deflated or inflated when the inlet  35  of the blood withdrawal lumen  33  is positioned in the distal aorta. 
         [0036]    Once blood is withdrawn from the subject, it can be mixed with an anticoagulant to keep the blood from coagulating. Exemplary anticoagulants include heparin, acid citrate dextrose, or sodium citrate. Typically, the anticoagulant is simply added via a syringe to a conduit containing the withdrawn blood. Alternatively, anticoagulant can be added within a withdrawing catheter prior to the blood actually exiting the subject. A catheter configured for such use, designated at  36  is illustrated schematically in  FIG. 4 . An anticoagulant infusion line  37  terminates within and near the end of the blood withdrawal lumen  38 . This catheter configuration enables anticoagulant to be introduced into the blood as the blood enters the catheter, and thus can reduce the degree of coagulation experienced by that blood. This catheter configuration can be combined with that described above in  FIG. 3  to enable blood withdrawn from the distal aorta to receive anticoagulant just as it leaves the bloodstream. 
         [0037]    After withdrawal, the blood is then oxygenated. Oxygenation can be performed in any manner known to those skilled in this art to oxygenate blood. For example, blood can be shunted into a tank or reservoir having an oxygen membrane and passed therethrough. 
         [0038]    In a variation the withdrawn blood be passed through a filter or other device that removes any blood clots or other debris prior to reinfusion, as such debris can adversely affect perfusion. 
         [0039]    Once the blood is oxygenated, it can be infused into the aorta of the subject. Typically between about 250 to 3000 milliliters of the blood are infused, with 750 to 2000 milliliters of the blood being a more preferred dosage. Perfusion should be carried out sufficiently rapidly to enhance cardiac electrical activity; in one variation, the perfusion duration is less than five minutes. 
         [0040]    Perfusion of the newly-oxygenated blood can be carried out continuously, or preferably can be carried out in a pulsatile rhythm. Perfusion with a pulsatile rhythm can assist in removing sludged blood cells from the microvasculature of the subject and may have positive effects on resuscitation due to the rheology of blood. In particular, perfusion with a pulsatile rhythm in which the perfusion “pulses” are timed to coincide with the decompression or relaxation phases of CPR (diastolic pulsing) can be especially effective. 
         [0041]    A vasoconstrictor may be employed in the methods described herein. Exemplary adrenergic vasoconstrictors include epinephrine, norepinephrine, methoxamine, phenylephrine, with epinephrine being preferred; nonadrenergic vasoconstrictors can also be used. Vasoconstrictors may be administered by any suitable means, such as by parenteral injection (e.g., intravenous injection, intraarterial injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, tracheobronchial administration), or by including the vasoconstrictor in the protective solution used to perfuse the aortic arch. In a variation the administration of the vasoconstrictor be concurrent with (i.e., sufficiently close in time to) perfusion of the aortic arch so that the vasoconstrictor will affect coronary perfusion with the autologous blood. The dosage of the vasoconstrictor will vary depending on the subject and the particular vasoconstrictor chosen, but will generally be between 0.002 and 0.3 mg/kg. 
         [0042]    Medicaments containing a vasoconstrictor for enhancing coronary perfusion with a protective solution during selective aortic arch perfusion may be prepared by contacting and mixing the vasoconstrictor with a pharmaceutically acceptable carrier, such as a sterile pyrogen-free saline solution, in accordance with techniques known in the pharmacy art. The pharmaceutical carrier may be the protective solution itself, such as a perfluorochemical blood-substitute solution as discussed above. 
         [0043]    Restoring spontaneous circulation in the subject may be carried out by any suitable means, such as electric shock or precordial thump (i.e., application of an external force), or by enhancing electrical activity through perfusion and other resuscitation techniques so that normal electrical activity re-emerges without application of an external force. An electric shock to heart muscle tissue which will restore spontaneous circulation from a chaotic electrical signal (or “defibrillation”) may be administered with any suitable defibrillator, such as the Responder™ 1500 (manufactured by Marquette Electronics, Milwaukee, Wis.). 
         [0044]    An exemplary SAAP apparatus  40  is schematically illustrated in  FIG. 3 . The apparatus  40  comprises a storage tank  41  having two upper ports  43 ,  44 , and a lower port  45 . A venous blood withdrawal line  46  is attached at one end to upper port  43  and at its other end to a venous blood withdrawal catheter  47  by a fitting  48 . The venous blood withdrawal catheter  47  is to be inserted into the femoral vein of a subject. An anticoagulant syringe  49  is also fluidly connected to the fitting  48  via a catheter, connector, or connector tubing  50 . An oxygenated blood infusion line  51  is attached at one end to the lower port  45 . As the oxygenated blood infusion line  51  extends away from the lower port  45 , it meets with and travels adjacent to the venous blood withdrawal line  46 . The adjacent sections of the lines  46 ,  51  are enclosed within a roller pump apparatus  52 , which comprises a pair of wheels  53  mounted on a rotary arm  54 . Rotation of the arm  54  causes the wheels  53  to contact the lines  46 ,  51  and thereby deliver blood or a blood substitute to and from the SAAP apparatus  40 . At its outlet end, the oxygenated blood infusion line  51  meets the outlet end of an oxygenated blood recirculation line  55  that extends thereto from the upper port  44 . An infusion line  56  extends from the junction of the lines  51 ,  55  to an infusion port  57  that is connected to the inlet end of a balloon catheter (not shown) that is to be inserted in the femoral artery of a subject. A syringe  42  is fluidly interconnected with the infusion line  56 . The storage tank  41  also includes an oxygen intake port  58  and an additional syringe port  59 . The venous blood withdrawal line  46  also includes an oxygen intake port  60  between the fitting  48  and the roller pump apparatus  52 . Three valves  61 ,  62 ,  63  are located, respectively, adjacent the fitting  48  on the venous blood withdrawal line  46 , on the oxygenated blood recirculation line  55 , and on the infusion line  56  between the syringe  42  and the infusion port  57 . A fourth valve  67  is located on the oxygen intake port  60 . A controller  65  is operably connected with the syringe  42  to control its operation and is also operably connected with a CPR device (indicated schematically at  66 ). The apparatus  40  may also include a valve (not shown) that can remove any air that enters the system prior to its being introduced into the subject&#39;s aorta. 
         [0045]    In operation, autologous blood is drawn from the subject into the femoral venous blood withdrawal catheter  47 . Anticoagulant, such as heparin, is added to the withdrawn blood through the anticoagulant syringe  49 . The venous blood is pumped through the venous blood withdrawal line  46  by the roller pump apparatus  52 ; as the rotary arm  54  rotates, the wheels  53  provide a positive pressure of the blood that forces it through the line  46 . The venous blood enters the storage tank  41  through upper port  43  and flows into the bottom portion of the storage tank  41 . Oxygen is continuously introduced into the storage tank through the oxygen intake port  58 . After the blood is oxygenated in the storage tank  41 , it flows therefrom through the lower port  45  into the oxygenated blood infusion line  51 . The blood is propelled by the action of the roller pump unit  52  to the infusion line  56 . Flow into the oxygenated blood recirculation line  55  is prevented because the valve  62  is in a closed position Oxygenated blood can be furnished in a pulsatile rhythm by reciprocating action from the syringe  42 . The oxygenated blood flows through the infusion line  56 , through the infusion port  57 , and into the SAAP catheter for delivery to the aorta. 
         [0046]    Similarly, this apparatus  40  can also be used to deliver a blood substitute to the subject. See U.S. Pat. No. 5,216,032 to Manning for a discussion of blood substitutes. The blood substitute can be introduced into the storage tank  41  through the syringe port  59 . The valves  61  and  62  are in their closed positions. The blood substitute follows the same path to the subject as that of oxygenated blood described above. 
         [0047]    Further, the apparatus  40  can be used to recirculate, and thereby thermally and hemodynamically prepare a blood substitute for perfusion. For recirculation of blood substitute, valve  63  is in its closed position, and valve  62  is in its open position. This creates a closed loop system that proceeds from the storage tank  41  to the oxygenated blood infusion line  51 , the recirculation line  55 , and the upper port  44  before returning to the storage tank  41 . 
         [0048]    Use of the apparatus  40  is exemplified by the following scenario. A physician arrives at the scene of a cardiac arrest patient and secures access to the femoral artery by either percutaneous or surgical means. The blood substitute is oxygenated during the vascular access procedure. The catheter is advanced to the thoracic aorta and epinephrine is administered into the aortic arch. The catheter balloon is inflated and an initial SAAP infusion of the blood substitute (which can contain reperfusion-injury combating agents) is performed. An initial bolus of blood substitute is rapidly infused to close the aortic valve and CPR is halted for the initial infusion lasting 30 to 60 seconds. This would assure that the myocardium was effectively perfused with the blood substitute. During this initial infusion, access to a femoral vein is secured. Aortic arch epinephrine administration can be titrated to maximize CPR-diastolic coronary perfusion pressure (CPP). Two to three minutes after the initiation of the first blood substitute infusion, a second blood substitute infusion is initiated. Pulsed diastolic infusion induced by the syringe  42  using half of the volume initially infused would be used to elevate CPP and diminish the volume effects of a second infusion. The infusion pulses are administered during the decompression and relaxation phases of CPR. During the second blood substitute infusion, femoral blood is withdrawn, anticoagulated via the anticoagulant syringe, oxygenated in the storage tank  41 , thermally treated (if necessary), and filtered in preparation for reinfusion. Depending upon the rapidity of femoral venous access and blood withdrawal, either a third blood substitute infusion similar to the second or an autologous blood infusion is initiated. Aortic arch epinephrine titration, other pharmacologic therapies, and repetitive or continuous autologous blood SAAP can be performed until return of spontaneous circulation (ROSC) is attained or the resuscitative efforts are halted. If ROSC is attained, autologous blood withdrawal and reinfusion could be continued (with or without the catheter balloon inflated depending, on the clinical situation) serving as partial cardiopulmonary bypass support for the still unstable cardiovascular system in the early post-resuscitation phase. Graded balloon inflation could be used to provide peripheral resistance as needed in the immediate and early post-resuscitation phase. 
         [0049]    In view of the considerable out-of-hospital use anticipated with the present invention, in a variation the SAAP apparatus be packaged to be easily portable. The apparatus can be packaged in a suitcase, attache case, backpack, or the like, and be easily carried to the patient for use by a physician or paramedic. 
         [0050]    The present invention may be beneficial in the management of traumatic and other nontraumatic/surgical causes of cardiac arrest or profound hypovolemia with impending cardiac arrest. In addition to rapid volume replacement, the catheter balloon could serve much like an aortic cross-clamp to significantly reduce or stop exsanguinating hemorrhage from the abdomen, pelvis, or lower extremities until the patient could be transferred to the operating room. Clinical situations where the present invention can be used include: blunt abdominal or multi-system trauma with profound hemorrhage/hypovolemia; penetrating abdominal trauma with profound hemorrhage/hypovolemia; ruptured abdominal aortic aneurysm with profound hypotension or impending arrest; and major pelvis fractures or disruption. In hemorrhagic/hypovolemic conditions, heterologous human blood, such as from a blood bank, may also be employed. 
         [0051]    Turning now to improved variations, the following devices and/or methods further assist in techniques for resuscitating a patient. The devices, methods, systems and other disclosure contained in U.S. Provisional No. 61/727,302 filed on Nov. 16, 2012 are incorporated by reference in its entirety. 
         [0052]      FIG. 6A  illustrates another variation of a device  106  having an expandable member  108 , where the device is positioned within the aorta  11  such that the distal end  112  is positioned within arterial flow of blood  2  within the aorta  11 . As illustrated in  FIG. 6A , an infused substance  3  is infused within a lumen of the device  106 . Typically, the infused substance comprises infused blood. However, other substances are within the scope of this disclosure. Regardless, flow of the infused substance within the catheter  106  is diverted within the expandable member  108 . The diversion can be accomplished in any number of ways, for example, an obturator  110  can be positioned within the device  106  to increase a fluid flow resistance at the distal end  112  of the device  106 . The obturator  110  can include an expandable member, a taper or other structure to prevent or resist the flow of the infused substance from the distal end  112  of the device  106 . The increased resistance to flow causes the infused substance to flow into an expandable member  108 , as shown in  FIG. 6B . Expansion of the expandable member  108  causing interruption of arterial flow  2 . Flow of the infused substance can occur in a space between the device  106  and the obturator  110 . Alternatively, the obturator  110  can include one or more lumens to provide flow of blood into the expandable member. In additional variations, the obturator can include one or more lumens for a guidewire or other such In an additional variation, the expandable member  108  can be located on a recess on the device  106  such that a diameter of the expandable member in a reduced profile is no greater than a diameter of the catheter body of the device. 
         [0053]      FIG. 7A  illustrates a partial cross sectional view of the device  105  with an obturator  110  extended therethrough when a flow of an infusion substance  3  is diverted into the expandable member  108 . As illustrated, the device  106  can include one or more valves  114 . The valves can be any structure that permits flow of the infusion substance  3  into the expandable member  108  and prevents the infusion substance from leaving the expandable member until desired. In one example, the valve can comprises a reed valve. 
         [0054]    Once the expandable member  108  is sufficiently expanded, either by forming a seal against the walls of the vessel to stop arterial blood flow, reaching a desired pressure, delivery of a volume of the infusion substance, etc. the flow resistance at the distal end  112  of the device  106  can be reduced (e.g., by removing the dilator as shown in  FIG. 7B ) such that the flow of the infusion substance  3  extends through the device  106  and out of the distal end  112 . In alternate variations, the dilator  110  can remain within the occlusion device  106  such that when pressure in the expandable member  108  reaches a threshold value, flow of the infusion substance is automatically directed through the distal end  112 . 
         [0055]      FIG. 8A  illustrates a portion of the device  106  without the expandable member. As shown, the valve  114  is in a closed position and allows flow of the infusion material from within the lumen of the device  105  into the expandable member. The valve  114  remains closed in the absence of pressure or flow from the device  106  lumen such that fluid within the expandable member cannot exit through the valve. 
         [0056]      FIG. 8B  illustrates a variation of the device  106  using a valve release mechanism  115  to open the valve and reduce the expandable member. The release mechanism can comprise any spring loaded structure that opens the valve  116  (or a separate valve). In one variation, the release mechanism  116  can be located on a portion of the dilator  110 , such that a physician can position the release mechanism  116  adjacent to the valve  114  when desired. Clearly, alternate variations of the device include a separate release mechanism. 
         [0057]    The device described above provides an improvement over conventional devices by maximizing the internal size of the infusion lumen while minimizing the external size of the catheter by eliminating the need for a separate inflation lumen. In additional variations, the obturator or device used to expand the expandable member can be a color that is different than a color of the device used to drain the expandable member. For example, the obturator can be green while the draining obturator can be red. 
         [0058]    Any of the variations described above can include an indicator that the expandable member is in the expanded state. Such an indicator could prevent attempted removal of the device from the vessel when expanded. The indicator can be a radiopaque marking, or other conventional tag to provide the status of the expandable member to the user. 
         [0059]    Naturally, the system may include a variation of the above configurations. Variations of the device may include systems that have various decorations on the outer surface to make the system more child-friendly and alleviate apprehension of getting an injection. In these devices and methods, the conditions may be those as described above, or other conditions as required by the specific treatment sought. 
         [0060]    While embodiments and applications of this invention have been shown and described, it would be apparent to those skilled in the art having the benefit of this disclosure that many more modifications than mentioned above are possible without departing from the inventive concepts herein The invention, therefore, is not to be restricted except in the spirit of the appended claims.